Roger Prades, PhD

Roger Prades has over 15 years of experience in the biotech sector, translating molecules from the bench to the bedside. His PhD focused on developing peptide brain shuttles to transport therapeutics across the blood-brain barrier (BBB) under physiological and pathological conditions. In 2011, he joined Iproteos as CSO, leading the development of PREP inhibitors for neurodegenerative diseases and selective MMP inhibitors for epilepsy treatment. In 2020, he joined Accure Therapeutics as Project Director, advancing disease-modifying therapies for the treatment of Parkinson’s disease, acute optic neuritis/multiple sclerosis, and epilepsy. His expertise spans medicinal chemistry, ADME, and translational drug development, ensuring that novel therapeutics effectively cross the BBB and deliver clinical benefits. He has authored multiple peer-reviewed publications and holds several patents.